Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

303
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
303
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.4K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer02:18

Cancer

47.1K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
47.1K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

4.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Body mass index and the acute hospitalization period considerations after traumatic spinal cord injury: A national database analysis.

Journal of clinical orthopaedics and trauma·2026
Same author

Declining Overall Use of Cervical Disk Arthroplasty in Medicare Beneficiaries Despite Outpatient Migration, 2016 to 2022.

Orthopedics·2026
Same author

The efficacy of ChatGPT as a student resource for the diagnosis and treatment of neck pain.

Disability and rehabilitation·2026
Same author

The impact of body mass index on traumatic spinal cord injury characteristics.

Journal of orthopaedics·2026
Same author

The mechanisms and risk factors of spinal cord injury with versus without concurrent vertebral fracture: A Spinal Cord Injury Model Systems database analysis.

The journal of spinal cord medicine·2026
Same author

Development and internal validation of a risk prediction calculator for minor spinal cord injury in CT-negative blunt trauma.

Injury·2026

Related Experiment Video

Updated: May 13, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.0K

Inequity of NIH cancer funding in the United States: an ecological study predicting funding based on disease burden

Eli Berglas1, David Musheyev1, Aaron B Lavi1

  • 1Department of Urology, State University of New York Downstate Health Sciences University, New York City, USA.

Lancet Regional Health. Americas
|April 16, 2025
PubMed
Summary

National Institutes of Health (NIH) funding for cancers shows significant disparities. Stomach cancer is most underfunded, while brain cancer receives excess funding, highlighting inequities in research allocation.

Keywords:
Burdens of diseaseCancerDALYEquityGlobal healthGrant fundingHealth disparityHealth economicsHealth policyMedical ethicsNIHNational institute of healthResearch funding

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:49

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

60

Related Experiment Videos

Last Updated: May 13, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.0K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:49

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

60

Area of Science:

  • Oncology
  • Health Services Research
  • Biostatistics

Background:

  • National Institutes of Health (NIH) funding allocation has historically used disease burden metrics.
  • Previous models included diseases with weak underlying relationships, potentially skewing funding decisions.
  • This study focuses on cancers to develop a more precise model for scrutinizing funding allocation.

Purpose of the Study:

  • To create a refined model for National Institutes of Health (NIH) funding allocation specifically for cancers.
  • To identify disparities in NIH funding based on cancer disease burden and public interest.
  • To quantify the extent of over/underfunding for various cancer types.

Main Methods:

  • An ecological study analyzed NIH funding data from 2008-2023.
  • Cancers were selected based on NIH Research Portfolio Online Reporting Tool and Global Burden of Disease (GBD) 2021 data.
  • Multivariable linear regression incorporated disability-adjusted life years (DALYs) and Google Trends data to model appropriate funding.

Main Results:

  • Fifteen cancers were included; neuroblastoma had the highest funding-to-DALY ratio, lung cancer the lowest.
  • Stomach cancer was most underfunded (197.9%), while brain cancer was most overfunded (64.1%).
  • Brain, breast, and colorectal cancers consistently showed overfunding (>40%), whereas leukemia, uterine, and stomach cancers were underfunded (<150% of expected).

Conclusions:

  • Cancer research funding by the NIH exhibits significant disparities, necessitating a reevaluation of allocation strategies.
  • The study's year-by-year analysis provides a framework for future research into NIH funding dynamics.
  • Public interest should be carefully weighed against disease burden to prevent popularity from unduly influencing funding decisions.